First quarter 2025 Total Revenue increased 18% year-over-year to $319.6 million First quarter 2025 Written Premium increased 12% year-over-year to $244.3 million First quarter 2025 Marketplace revenue increased 176% year-over-year to $29.0 million First quarter 2025 Operating Income increased 110% year-over-year to $25.7 million …
Immunocore Holdings plc Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for …
Lantheus Holdings, Inc. Worldwide revenue of $372.8 million in the first quarter 2025 GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first …
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with nasal polyps, analysis showed improvements in both symptoms and polyp size in Sham …
Prioritization of Free Cash Flow to Accelerate Share Repurchases Increase of Shares Available for Buyback to 11.4 million shares, an increase of 7.5 million shares Operating income of $141 million as compared to $137 million in prior year Adjusted EBITDA of $182 million as …
By migrating the Perpay Credit Card to Marqeta’s modern credit platform, Perpay intends to scale its offering with additional flexibility and control to meet the needs of its growing customer base. OAKLAND, Calif., May 07, 2025--(BUSINESS WIRE)--Marqeta, Inc. (NASDAQ: MQ), the global modern card …
Study published in American Journal of Transplantation highlights strong sensitivity and specificity, along with a >37% reduction in false positives when using Prospera Heart with DQS Adds to the growing body of evidence supporting DQS for dd-cfDNA analysis in solid organ transplant AUSTIN, Texas, …
Strong Sales Momentum; Updates Full-Year Financial Guidance Third-Quarter Fiscal 2025 Highlights Total case volume increased 10.0% Total Independent Foodservice case volume increased 20.0% Organic Independent Foodservice case volume increased 3.4% Net sales increased 10.5% to $15.3 billion Gross profit improved 16.2% to $1.8 billion …
Rhythm Pharmaceuticals, Inc. -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- …
ST. GEORGE, Utah, May 07, 2025--(BUSINESS WIRE)--On May 6, 2025, the Board of Directors (the "Board") of SkyWest, Inc. (NASDAQ: SKYW) ("SkyWest") approved a $250 million increase to its existing share repurchase plan. SkyWest is authorized to repurchase such shares of common stock at …